drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Type II glycoengineered anti-CD20 monoclonal antibody (Gazyva) that binds CD20 on mature/memory B cells, enhancing ADCC and direct cell death with reduced CDC versus rituximab, resulting in B-cell depletion and reduced antiplatelet autoantibody production.
nci_thesaurus_concept_id
C70741
nci_thesaurus_preferred_term
Obinutuzumab
nci_thesaurus_definition
A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.
drug_mesh_term
obinutuzumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Glycoengineered type II anti‑CD20 IgG1 that binds CD20 on mature/memory B cells with increased FcγRIII affinity, driving enhanced ADCC/ADCP and direct, caspase‑independent cell death (with reduced CDC), resulting in B‑cell depletion and decreased pathogenic autoantibody production.
drug_name
Obinutuzumab
nct_id_drug_ref
NCT05995054